The major goal of this reentry application is to facilitate Dr. Patrick Bilders reengagement with science. Dr. Bilder has experienced a recent two-and-a-half year diversion from his career path due to illness. The scientific component of the re-entry application, which aims at characterizing the cell envelope constituents of a set of Mycobacterium tuberculosis (Mtb) mutants with the ability to enhance macrophage tumor necrosis factor (TNF) production, derives from the results generated by an on-going P01 program, on which I am the PI of Project 3. A major component of Project 3 of the P01 Program is to develop effective TB vaccines by targeting Mtb TNFregulating genes to generate mutants with enhanced immunogenecity. This strategy is based on the ability of TNF to promote apoptosis and phagolysosomal fusion, two cellular processes known to augment immunogenicity of an immunological reaction by enhancing cross-priming of cytotoxic CD8 T cells and antigen presentation;respectively. Using a genetic screen, we have identified a set of Mtb genes whose disruption results in mutants with TNF-upregulating phenotype in infected macrophages. In line with the above-stated properties of TNF and validating our vaccine development strategy, these mutants promote apoptosis and phagolysosomal fusion in macrophages and imunization of C57BL/6 mice with these strains elicit a Th1 response superior to that engendered by the wildtype (WT) Mtb strain H37Rv. These TNF-upregulating mutants are disrupted for genes that have been annotated to encode functions capable of modulating the Mtb cell envelope components. The overall goal of this application is to test the hypothesis that the cell envelope of the TNF-upregulating Mtb mutants are different than that of the WT strain, thus resulting in altered interaction with host macrophages, leading to enhanced TNF production by the phagocytes upon infection. To ensure the success of Dr. Bilders re-entry into science, we have in place a plan that incorporates bench experience, career development opportunities, multiple venues for scientific intearctions, and didactic courses;in addition, a well established TB investigators with experience pertinent to the subject matter of the proposal -- Dr. Jordi Torrelles (Ohio State University) has been enlisted as Dr. Bilders Co-mentor. We believe this proposal will successfully facilitate Dr. Bilders re-entry into science and will likely yield information that will shed light on the mechanisms underlying the TNF-enhancing attributes of the Mtb deletion strains, which may, in turn, lead to the development of novel effective anti-TB vaccines.
Mycobacterium tuberculosis, the bacterium that causes tuberculosis (TB), remains a major threat to public health worldwide. It has been estimated that one-third of the worlds population has been infected with the tubercle bacillus. It is generally believed that a major proportion of those infected harbors latent bacteria that can subsequently reactivate to cause disease and disseminate. A most effective way to control an infectious agent is to render the human resistant through vaccination. The efficacy of the existing anti-TB vaccine is inconsistent. We have generated mutant strains of M. tuberculosis that display enhanced immunogenicity. These strains were produced by disrupting M. tuberculosis genes that decrease the capacity of host cells to make tumor necrosis factor (TNF), a molecule made by white blood cells that can confer resistance against pathogens and boost immune response. By disruptingM. tuberculosis genes that can decrease the ability of white blood cells to make TNF, we have observed that the resulting mutant strains enhance TNF production. Testing these strains in laboratory animals has revealed that they display enhanced immunogenicity. The current research program is designed to understand how these mutant strains increase the capacity of white blood cells to make TNF. We hypothesize that there are alterations in the cell envelope of the mutant M. tuberculosis that augment white blood cell TNF production. We will profile the cell envelope constituents of the mutants and byso doing, we believe it is possible to discover molecules from these mutants that can help make more effective anti-TB vaccines.
Showing the most recent 10 out of 64 publications
